Navigation Links
Sundia MediTech Appoints Dr. Tong Xu as VP of Process Chemistry
Date:6/29/2009

SHANGHAI, June 29 /PRNewswire-Asia/ -- Sundia MediTech Company, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr. Tong Xu has been appointed Vice President of Process Chemistry Services.

Prior to joining Sundia, Dr. Xu worked at La Jolla Pharmaceutical Company, an R&D based biotech company in San Diego, USA for 12 years. At La Jolla Pharmaceutical Company, Dr. Xu rose through the ranks from Research Scientist, to Manager, Senior Manager, and Associate Director of Process Development. Through this career path, he accumulated extensive experience in developing and managing process chemistry programs. His accomplishments include directing process development effort of Riquent(R) at clinical phase III and pre-commercialization stage.

"I am very pleased to welcome Dr. Xu to join Sundia. He is not only an outstanding scientist and research fellow, but also an experienced business manager," said Dr. Xiaochuan Wang, Chairman and CEO of Sundia. "Dr. Xu led the effort in his previous employment to search, select, negotiate and qualify CRO service providers in GLP and cGMP production of raw materials, starting materials, and API intermediates. This experience is very valuable for his new role to lead process chemistry CRO services at Sundia."

Dr. Xu received his bachelor's degree in Chemistry from Nankai University, and his Ph.D. degree in Organic Chemistry from the University of Michigan in USA. He also obtained an MBA with focus on finance and entrepreneurship from the Anderson School of Management at UCLA in USA.

About Sundia: Sundia MediTech Company is a leading integrated pharmaceutical contract research organization (CRO) company based in Shanghai, China, to provide R&D outsourcing services to biotech and pharmaceutical companies worldwide, ranging from early hit screening, biological service, lead optimization, DMPK, candidate preclinical development, formulation development, API manufacture, and regulatory submission. For more information, please visit http://www.sundia.com .


'/>"/>
SOURCE Sundia MediTech Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
2. Sundias Animal Facility Passed Client and Government Inspection
3. Sundia MediTech in Deloitte Technology Fast 500 Asia Pacific List
4. Sundia MediTech and Xcovery Announce Big Success in Drug Discovery
5. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
6. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
7. Novavax Appoints Stanley Erck to Board of Directors
8. Qforma Appoints Four Executives in Sales and Field Operations
9. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
10. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
11. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... 2 diabetes, announced that it has obtained a ... vector developed in the laboratory of Professor ... The company plans to use this vector in ... "Early research has shown promise ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), ... panel range with the launch of the SureSeq myPanel™ NGS ... variants in familial hypercholesterolemia (FH). The panel delivers single nucleotide ... single small panel and allows customisation by ,mix and match, ... for LDLR , P C SK9 ...
(Date:12/8/2016)... ... , ... This CAST literature review and report looks at problems caused by ... economic effects in countries that are major global commodity exporters and importers, which show ... of low level presence (LLP) puts large volumes of trade worth billions of dollars ...
(Date:12/8/2016)... SEOUL, South Korea , Dec. 8, 2016 /PRNewswire/ ... completed a $21 billion KRW (US $18.9M) Series A ... Management, Kolon Investment, G.N. Tech Venture and SNU Bio ... by Eutilex to 30.5 billion KRW (US $27.7M) since ... will help Eutilex to bolster the development and commercialization ...
Breaking Biology Technology:
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/27/2016)... DUBLIN , June 27, 2016 Research ... in North America 2016-2020" report to their offering. ... North America to grow at a CAGR ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):